1 | mortality | 58,246 |
2 | morality | 77 |
3 | mortality/hospitalization | 18 |
4 | tfcs | 13 |
5 | re-incarceration | 11 |
6 | ppmi | 10 |
7 | hiv-transmission | 9 |
8 | loculation | 9 |
9 | pdtg | 9 |
10 | dehydrocostuslactone | 8 |
11 | analgesia/anaesthesia | 7 |
12 | n29 | 6 |
13 | neovasculogenesis | 6 |
14 | remanipulation | 6 |
15 | splay | 6 |
16 | step-counts | 6 |
17 | death/stroke/mi | 5 |
18 | fmd/shear | 5 |
19 | /m/ | 4 |
20 | australia/japan | 4 |
21 | beta-activity | 4 |
22 | cholesterol-levels | 4 |
23 | death/stroke | 4 |
24 | et-1/no | 4 |
25 | eyestrain | 4 |
26 | f-hbsag | 4 |
27 | incidence/mortality | 4 |
28 | nf-κb/p65 | 4 |
29 | snail1 | 4 |
30 | stroke-death | 4 |
31 | 3-hydroxyphenazepam | 3 |
32 | assisted-patency | 3 |
33 | gd15 | 3 |
34 | jobless | 3 |
35 | neuromorbidity | 3 |
36 | non-o139 | 3 |
37 | pbd10 | 3 |
38 | periopathogens | 3 |
39 | post-mch | 3 |
40 | recurrence-risk | 3 |
41 | scleroma | 3 |
42 | t14 | 3 |
43 | 1-year-mortality | 2 |
44 | 230-350 | 2 |
45 | 30-day-mortality | 2 |
46 | a-δ-amplitudes | 2 |
47 | amputation/occlusion | 2 |
48 | anti-dnase-b | 2 |
49 | betab-subunits | 2 |
50 | boane | 2 |
51 | calciuresis | 2 |
52 | cellular-src | 2 |
53 | ct-spect | 2 |
54 | cuddliness | 2 |
55 | culture-positivity | 2 |
56 | edab-pb | 2 |
57 | epimesembranol | 2 |
58 | hongjingtian | 2 |
59 | incertitude | 2 |
60 | jermuk | 2 |
61 | kokujev | 2 |
62 | lg09 | 2 |
63 | lvmv-ratio | 2 |
64 | mortality/hospitalisation | 2 |
65 | nnal-glucuronide | 2 |
66 | one-half-fold | 2 |
67 | piezophila | 2 |
68 | post-chemoradiotherapy | 2 |
69 | pseudovivipary | 2 |
70 | ptca/cabg | 2 |
71 | re-ischaemia | 2 |
72 | reinfarction/reischemia | 2 |
73 | reperfusion/recanalization | 2 |
74 | stroke/death/tia | 2 |
75 | thymoleptics | 2 |
76 | trimethoprim-sulfamethoxasole | 2 |
77 | 0.40/month | 1 |
78 | 1,266,851 | 1 |
79 | 1.5-4-fold | 1 |
80 | 16.8±51.5 | 1 |
81 | 18,500/µl | 1 |
82 | 181.67 | 1 |
83 | 3-oxopentannitrile | 1 |
84 | 43°±9° | 1 |
85 | 61.38-fold | 1 |
86 | 65°±13° | 1 |
87 | alditols | 1 |
88 | alkaline-labile | 1 |
89 | arteriolarization | 1 |
90 | atherogenity | 1 |
91 | atheroprogression | 1 |
92 | bodyequilibrium | 1 |
93 | casefatality | 1 |
94 | cellobiose-ldl | 1 |
95 | cephalosporins.uti | 1 |
96 | clinical-financial | 1 |
97 | clot-stability | 1 |
98 | colonizzation | 1 |
99 | cp-relatedspasticity | 1 |
100 | crispiness | 1 |
101 | death/shock/chf | 1 |
102 | dialysis-dependence | 1 |
103 | drink-driving/riding | 1 |
104 | edemagenesis | 1 |
105 | evaluation-are | 1 |
106 | functional-residual-capacity | 1 |
107 | hospitalization/mortality | 1 |
108 | immunocompetences | 1 |
109 | insulin-secretion | 1 |
110 | kir3.2 | 1 |
111 | maaco1expression | 1 |
112 | markedly-effective | 1 |
113 | menthol- | 1 |
114 | mibakuekkito | 1 |
115 | micro-closures | 1 |
116 | mortality-hsd | 1 |
117 | mortalitystudy | 1 |
118 | motality | 1 |
119 | mppc | 1 |
120 | n-methyl-d-aspartic-acid-related | 1 |
121 | neuroinvasiveness | 1 |
122 | occusion | 1 |
123 | ofanemia | 1 |
124 | off/28-day | 1 |
125 | operative-delivery | 1 |
126 | out.comes | 1 |
127 | post-ext | 1 |
128 | punitiveness | 1 |
129 | refractivity | 1 |
130 | serum-bnp | 1 |
131 | smallscaleinteractions | 1 |
132 | survival-hsd | 1 |
133 | them-both | 1 |
134 | therapy-months | 1 |
135 | tncs | 1 |
136 | under-prediction | 1 |
137 | viminale | 1 |
138 | α-lipoprotein | 1 |
1 | /m/ | 4 |
2 | 0.40/month | 1 |
3 | 1,266,851 | 1 |
4 | 1-year-mortality | 2 |
5 | 1.5-4-fold | 1 |
6 | 16.8±51.5 | 1 |
7 | 18,500/µl | 1 |
8 | 181.67 | 1 |
9 | 230-350 | 2 |
10 | 3-hydroxyphenazepam | 3 |
11 | 3-oxopentannitrile | 1 |
12 | 30-day-mortality | 2 |
13 | 43°±9° | 1 |
14 | 61.38-fold | 1 |
15 | 65°±13° | 1 |
16 | a-δ-amplitudes | 2 |
17 | alditols | 1 |
18 | alkaline-labile | 1 |
19 | amputation/occlusion | 2 |
20 | analgesia/anaesthesia | 7 |
21 | anti-dnase-b | 2 |
22 | arteriolarization | 1 |
23 | assisted-patency | 3 |
24 | atherogenity | 1 |
25 | atheroprogression | 1 |
26 | australia/japan | 4 |
27 | beta-activity | 4 |
28 | betab-subunits | 2 |
29 | boane | 2 |
30 | bodyequilibrium | 1 |
31 | calciuresis | 2 |
32 | casefatality | 1 |
33 | cellobiose-ldl | 1 |
34 | cellular-src | 2 |
35 | cephalosporins.uti | 1 |
36 | cholesterol-levels | 4 |
37 | clinical-financial | 1 |
38 | clot-stability | 1 |
39 | colonizzation | 1 |
40 | cp-relatedspasticity | 1 |
41 | crispiness | 1 |
42 | ct-spect | 2 |
43 | cuddliness | 2 |
44 | culture-positivity | 2 |
45 | death/shock/chf | 1 |
46 | death/stroke | 4 |
47 | death/stroke/mi | 5 |
48 | dehydrocostuslactone | 8 |
49 | dialysis-dependence | 1 |
50 | drink-driving/riding | 1 |
51 | edab-pb | 2 |
52 | edemagenesis | 1 |
53 | epimesembranol | 2 |
54 | et-1/no | 4 |
55 | evaluation-are | 1 |
56 | eyestrain | 4 |
57 | f-hbsag | 4 |
58 | fmd/shear | 5 |
59 | functional-residual-capacity | 1 |
60 | gd15 | 3 |
61 | hiv-transmission | 9 |
62 | hongjingtian | 2 |
63 | hospitalization/mortality | 1 |
64 | immunocompetences | 1 |
65 | incertitude | 2 |
66 | incidence/mortality | 4 |
67 | insulin-secretion | 1 |
68 | jermuk | 2 |
69 | jobless | 3 |
70 | kir3.2 | 1 |
71 | kokujev | 2 |
72 | lg09 | 2 |
73 | loculation | 9 |
74 | lvmv-ratio | 2 |
75 | maaco1expression | 1 |
76 | markedly-effective | 1 |
77 | menthol- | 1 |
78 | mibakuekkito | 1 |
79 | micro-closures | 1 |
80 | morality | 77 |
81 | mortality | 58,246 |
82 | mortality-hsd | 1 |
83 | mortality/hospitalisation | 2 |
84 | mortality/hospitalization | 18 |
85 | mortalitystudy | 1 |
86 | motality | 1 |
87 | mppc | 1 |
88 | n-methyl-d-aspartic-acid-related | 1 |
89 | n29 | 6 |
90 | neovasculogenesis | 6 |
91 | neuroinvasiveness | 1 |
92 | neuromorbidity | 3 |
93 | nf-κb/p65 | 4 |
94 | nnal-glucuronide | 2 |
95 | non-o139 | 3 |
96 | occusion | 1 |
97 | ofanemia | 1 |
98 | off/28-day | 1 |
99 | one-half-fold | 2 |
100 | operative-delivery | 1 |
101 | out.comes | 1 |
102 | pbd10 | 3 |
103 | pdtg | 9 |
104 | periopathogens | 3 |
105 | piezophila | 2 |
106 | post-chemoradiotherapy | 2 |
107 | post-ext | 1 |
108 | post-mch | 3 |
109 | ppmi | 10 |
110 | pseudovivipary | 2 |
111 | ptca/cabg | 2 |
112 | punitiveness | 1 |
113 | re-incarceration | 11 |
114 | re-ischaemia | 2 |
115 | recurrence-risk | 3 |
116 | refractivity | 1 |
117 | reinfarction/reischemia | 2 |
118 | remanipulation | 6 |
119 | reperfusion/recanalization | 2 |
120 | scleroma | 3 |
121 | serum-bnp | 1 |
122 | smallscaleinteractions | 1 |
123 | snail1 | 4 |
124 | splay | 6 |
125 | step-counts | 6 |
126 | stroke-death | 4 |
127 | stroke/death/tia | 2 |
128 | survival-hsd | 1 |
129 | t14 | 3 |
130 | tfcs | 13 |
131 | them-both | 1 |
132 | therapy-months | 1 |
133 | thymoleptics | 2 |
134 | tncs | 1 |
135 | trimethoprim-sulfamethoxasole | 2 |
136 | under-prediction | 1 |
137 | viminale | 1 |
138 | α-lipoprotein | 1 |
1 | menthol- | 1 |
2 | /m/ | 4 |
3 | pbd10 | 3 |
4 | 230-350 | 2 |
5 | 1,266,851 | 1 |
6 | snail1 | 4 |
7 | kir3.2 | 1 |
8 | t14 | 3 |
9 | 16.8±51.5 | 1 |
10 | gd15 | 3 |
11 | nf-κb/p65 | 4 |
12 | 181.67 | 1 |
13 | lg09 | 2 |
14 | n29 | 6 |
15 | non-o139 | 3 |
16 | re-ischaemia | 2 |
17 | reinfarction/reischemia | 2 |
18 | ofanemia | 1 |
19 | analgesia/anaesthesia | 7 |
20 | stroke/death/tia | 2 |
21 | piezophila | 2 |
22 | scleroma | 3 |
23 | anti-dnase-b | 2 |
24 | edab-pb | 2 |
25 | mppc | 1 |
26 | cellular-src | 2 |
27 | n-methyl-d-aspartic-acid-related | 1 |
28 | 1.5-4-fold | 1 |
29 | 61.38-fold | 1 |
30 | one-half-fold | 2 |
31 | survival-hsd | 1 |
32 | mortality-hsd | 1 |
33 | dialysis-dependence | 1 |
34 | nnal-glucuronide | 2 |
35 | incertitude | 2 |
36 | death/stroke | 4 |
37 | viminale | 1 |
38 | alkaline-labile | 1 |
39 | 3-oxopentannitrile | 1 |
40 | trimethoprim-sulfamethoxasole | 2 |
41 | boane | 2 |
42 | dehydrocostuslactone | 8 |
43 | evaluation-are | 1 |
44 | markedly-effective | 1 |
45 | death/shock/chf | 1 |
46 | f-hbsag | 4 |
47 | ptca/cabg | 2 |
48 | drink-driving/riding | 1 |
49 | pdtg | 9 |
50 | post-mch | 3 |
51 | stroke-death | 4 |
52 | 0.40/month | 1 |
53 | them-both | 1 |
54 | death/stroke/mi | 5 |
55 | ppmi | 10 |
56 | cephalosporins.uti | 1 |
57 | recurrence-risk | 3 |
58 | jermuk | 2 |
59 | clinical-financial | 1 |
60 | cellobiose-ldl | 1 |
61 | epimesembranol | 2 |
62 | 18,500/µl | 1 |
63 | 3-hydroxyphenazepam | 3 |
64 | bodyequilibrium | 1 |
65 | hongjingtian | 2 |
66 | australia/japan | 4 |
67 | eyestrain | 4 |
68 | α-lipoprotein | 1 |
69 | atheroprogression | 1 |
70 | maaco1expression | 1 |
71 | hiv-transmission | 9 |
72 | occusion | 1 |
73 | amputation/occlusion | 2 |
74 | loculation | 9 |
75 | remanipulation | 6 |
76 | re-incarceration | 11 |
77 | mortality/hospitalisation | 2 |
78 | reperfusion/recanalization | 2 |
79 | mortality/hospitalization | 18 |
80 | arteriolarization | 1 |
81 | colonizzation | 1 |
82 | under-prediction | 1 |
83 | insulin-secretion | 1 |
84 | lvmv-ratio | 2 |
85 | et-1/no | 4 |
86 | mibakuekkito | 1 |
87 | serum-bnp | 1 |
88 | fmd/shear | 5 |
89 | tfcs | 13 |
90 | thymoleptics | 2 |
91 | tncs | 1 |
92 | immunocompetences | 1 |
93 | a-δ-amplitudes | 2 |
94 | out.comes | 1 |
95 | micro-closures | 1 |
96 | therapy-months | 1 |
97 | edemagenesis | 1 |
98 | neovasculogenesis | 6 |
99 | calciuresis | 2 |
100 | cholesterol-levels | 4 |
101 | alditols | 1 |
102 | periopathogens | 3 |
103 | smallscaleinteractions | 1 |
104 | jobless | 3 |
105 | neuroinvasiveness | 1 |
106 | punitiveness | 1 |
107 | cuddliness | 2 |
108 | crispiness | 1 |
109 | betab-subunits | 2 |
110 | step-counts | 6 |
111 | ct-spect | 2 |
112 | post-ext | 1 |
113 | kokujev | 2 |
114 | off/28-day | 1 |
115 | splay | 6 |
116 | assisted-patency | 3 |
117 | mortalitystudy | 1 |
118 | post-chemoradiotherapy | 2 |
119 | pseudovivipary | 2 |
120 | operative-delivery | 1 |
121 | functional-residual-capacity | 1 |
122 | cp-relatedspasticity | 1 |
123 | neuromorbidity | 3 |
124 | morality | 77 |
125 | casefatality | 1 |
126 | motality | 1 |
127 | mortality | 58,246 |
128 | 1-year-mortality | 2 |
129 | 30-day-mortality | 2 |
130 | incidence/mortality | 4 |
131 | hospitalization/mortality | 1 |
132 | clot-stability | 1 |
133 | atherogenity | 1 |
134 | beta-activity | 4 |
135 | refractivity | 1 |
136 | culture-positivity | 2 |
137 | 65°±13° | 1 |
138 | 43°±9° | 1 |